Thera-SAbDab

DOVANVETMAB

>   Structural Summary
TherapeuticDovanvetmab
TargetIL31 (Feline)
Heavy ChainQVLLVQSGAEVRTPGASVKIFCKASGYSFTSYTIHWLRQAPAQGLEWMGNINPTSGYTENNQRFKDRLTLTADTSTNTAYMELSSLRSADTAMYYCARWGFKYDGEWSFDVWGAGTTVTVSS
Light ChainEIQMTQSPSSLSASPGDRVTITCRASQGISIWLSWYQQKPGNIPKVLINKASNLHIGVPSRFSGSGSGTDFTLTISSLEPEDAATYYCLQSQTYPLTFGGGTKLEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatFeline Whole mAb
IsotypeG1
Highest Clinical Trial (June '19)Unknown
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2019
INN Year Recommended2020
Companies Involvedna
Conditions Approvedna
Conditions Activena
Conditions Discontinuedna
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]